Article

FISH assay may be useful monitor of TCC recurrence

Jena, Germany-The fluorescence in situ hybridization (FISH) assay appears to be a useful, noninvasive method to monitor for tumor recurrence in patients with transitional cell carcinoma of the bladder, according to European researchers.

Related Videos
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Woman talking with doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
Alternative treatments and patient communication for genitourinary syndrome of menopause
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Sarah Razavi, MD, answers a question during a Zoom video interview
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
1 expert in this video
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
2 experts are featured in this series.
Treatment or Lack of Treatment of Small Renal Masses
1 expert is featured in this series.
The current treatment landscape of mHSPC
2 experts are featured in this series.
Strengths and Weaknesses of Imaging Modalities in ccRCC
1 expert in this video
BPH: Strategies for Guiding Patients From Medication to Intervention
Related Content
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
May 21st 2025

FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

Hannah Clarke
The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
May 20th 2025

Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer

Hannah Clarke
Results from the phase 3 AMPLIFY trial are intended to support an application to the FDA for potential approval of 64Cu-SAR-bisPSMA.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Woman talking with a doctor | Image Credit: © pucko_ns - stock.adobe.com
May 20th 2025

Experts share insights on next-generation NMIBC therapies

Urology Times staff
A recent Urology Times Clinical Forum provided an in-depth overview of current and emerging strategies for managing NMIBC.
Study shows value of precision-based approaches in prostate cancer
May 19th 2025

Study shows value of precision-based approaches in prostate cancer

Hannah Clarke
The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.
© 2025 MJH Life Sciences

All rights reserved.